Cancer bronchique non à petites cellules: la 2e ligne et au-delÃ

International recommendations assume that is proposed, after a first line containing a platinum salt, a second-line treatment for patients who maintained a good performance status. This treatment may appeal to docetaxel to pemetrexed or erlotinib. Several avenues are opened for the third exacerbation. It is recommended to propose the inclusion in a clinical trial.